COMPANY

ProEncia Biotechnology

Profile checked Oct 10, 2026

Funding and NIH signals

SEC Form D raise Form D reports $1.51M sold since 2024 (filed Aug 26, 2026). SEC Form D 0002103044-26-000001 (Aug 26, 2026)
Evidence (1 event)
- Aug 26, 2026 · SEC Form D 0002103044-26-000001
  Name of Issuer: ProEncia Biotechnology Inc.; CIK: 2103044; Address: Woodbury, MN; Submission type: D; Filing date: 2026-08-26; Industry Group: Biotechnology; Date of First Sale: 2024-10-04; Types of Securities Offered: Equity, Debt; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 1510000; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Raise Pre-seed · amount not disclosed · announced May 19, 2026 Company release ↗
Source quote
- May 19, 2026 · Company release ↗
  “MINNEAPOLIS--( BUSINESS WIRE )--Twin Cities-based ProEncia Biotechnology, a biopharma startup, today announced the company has closed significant pre-seed funding to advance its next-generation periodontal disease treatment”

From the company’s own releases; this list is partial. All raises and deals

May 19, 2026 Raise Private equity round — Pre-Seed: amount not published, announced May 19, 2026. Source: company's own press page. source ↗
May 19, 2026 Raise Pre-seed · amount not disclosed source ↗

Raised: amount not published. Last 2 years.

May 19, 2026 Private equity round — Pre-Seed: amount not published, announced May 19, 2026. Source: company's own press page. source ↗